Superior vena cava angiosarcoma

Summary

Superior vena cava angiosarcoma (MONDO:0003032) is a disease. A subtype of vein disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	superior vena cava angiosarcoma
Mondo ID	MONDO:0003032
DOID	DOID:4522
NCIT	C5378
UMLS	C1336530
MedGen	234373
GARD	0023338
Anatomy (UBERON)	UBERON:0001585
Is cancer (heuristic)	no

Also known as: angiosarcoma (disease) of anterior vena cava · angiosarcoma of Superior vena cava · angiosarcoma of the Superior vena cava · anterior vena cava angiosarcoma (disease)

Disease family

This is a subtype of vein disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › superior vena cava angiosarcoma

Related subtypes (12): venous insufficiency, portal vein thrombosis, occlusion of tributary of retinal vein, central retinal vein occlusion, cavernous sinus meningioma, pulmonary vein leiomyosarcoma, phlebitis, malignant jugulotympanic paraganglioma, varicose disease, vein of Galen aneurysm, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis

Subtypes (1): superior vena cava leiomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.